| B lymphocytes secrete antigen-presenting vesicles. G Raposo, HW Nijman, W Stoorvogel, R Liejendekker, CV Harding, ... The Journal of experimental medicine 183 (3), 1161-1172, 1996 | 4326 | 1996 |
| ESMO-ESGO-ESTRO consensus conference on endometrial cancer: diagnosis, treatment and follow-up N Colombo, C Creutzberg, F Amant, T Bosse, A González-Martín, ... International Journal of Gynecological Cancer 26 (1), 2-30, 2016 | 2060 | 2016 |
| The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis MJM Gooden, GH de Bock, N Leffers, T Daemen, HW Nijman British journal of cancer 105 (1), 93-103, 2011 | 1482 | 2011 |
| Improved risk assessment by integrating molecular and clinicopathological factors in early-stage endometrial cancer—combined analysis of the PORTEC cohorts E Stelloo, RA Nout, EM Osse, IJ Jürgenliemk-Schulz, JJ Jobsen, ... Clinical cancer research 22 (16), 4215-4224, 2016 | 792 | 2016 |
| Tumor-infiltrating lymphocytes in the immunotherapy era ST Paijens, A Vledder, M de Bruyn, HW Nijman Cellular & molecular immunology 18 (4), 842-859, 2021 | 719 | 2021 |
| Molecular classification of the PORTEC-3 trial for high-risk endometrial cancer: impact on prognosis and benefit from adjuvant therapy A León-Castillo, SM De Boer, ME Powell, LR Mileshkin, HJ Mackay, ... Journal of Clinical Oncology 38 (29), 3388-3397, 2020 | 656 | 2020 |
| Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre … SM De Boer, ME Powell, L Mileshkin, D Katsaros, P Bessette, ... The lancet oncology 19 (3), 295-309, 2018 | 638 | 2018 |
| Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer N Leffers, MJM Gooden, RA de Jong, BN Hoogeboom, KA ten Hoor, ... Cancer Immunology, Immunotherapy 58, 449-459, 2009 | 569 | 2009 |
| Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative E Stelloo, T Bosse, RA Nout, HJ MacKay, DN Church, HW Nijman, ... Modern pathology 28 (6), 836-844, 2015 | 476 | 2015 |
| Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a … SM de Boer, ME Powell, L Mileshkin, D Katsaros, P Bessette, ... The lancet oncology 20 (9), 1273-1285, 2019 | 452 | 2019 |
| Quality of life after pelvic radiotherapy or vaginal brachytherapy for endometrial cancer: first results of the randomized PORTEC-2 trial RA Nout, H Putter, IM Jürgenliemk-Schulz, JJ Jobsen, LCHW Lutgens, ... Journal of Clinical Oncology 27 (21), 3547-3556, 2009 | 350 | 2009 |
| Somatic POLE proofreading domain mutation, immune response, and prognosis in colorectal cancer: a retrospective, pooled biomarker study E Domingo, L Freeman-Mills, E Rayner, M Glaire, S Briggs, L Vermeulen, ... The lancet Gastroenterology & hepatology 1 (3), 207-216, 2016 | 332 | 2016 |
| POLE proofreading mutations elicit an antitumor immune response in endometrial cancer IC van Gool, FA Eggink, L Freeman-Mills, E Stelloo, E Marchi, M de Bruyn, ... Clinical Cancer Research 21 (14), 3347-3355, 2015 | 330 | 2015 |
| In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild‐type p53 JGA Houbiers, HW Nijman, SH Van Der Burg, JW Drijfhout, P Kenemans, ... European Journal of Immunology 23 (9), 2072-2077, 1993 | 329 | 1993 |
| Myeloid derived suppressor cells—an overview of combat strategies to increase immunotherapy efficacy O Draghiciu, J Lubbers, HW Nijman, T Daemen Oncoimmunology 4 (1), e954829, 2015 | 306 | 2015 |
| Lymphvascular space involvement: an independent prognostic factor in endometrial cancer JM Briët, H Hollema, N Reesink, JG Aalders, MJE Mourits, KA ten Hoor, ... Gynecologic oncology 96 (3), 799-804, 2005 | 299 | 2005 |
| Presence of tumor-infiltrating lymphocytes is an independent prognostic factor in type I and II endometrial cancer RA De Jong, N Leffers, HM Boezen, KA Ten Hoor, AGJ van der Zee, ... Gynecologic oncology 114 (1), 105-110, 2009 | 277 | 2009 |
| Identification of peptide sequences that potentially trigger HLA‐A2. 1‐restricted cytotoxic T lymphocytes HW Nijman, JGA Houbiers, MPM Vierboom, SH van der Burg, ... European journal of immunology 23 (6), 1215-1219, 1993 | 277 | 1993 |
| Tumor eradication by wild-type p53-specific cytotoxic T lymphocytes MPM Vierboom, HW Nijman, R Offringa, EIH Voort, T Hall, L Broek, ... The Journal of experimental medicine 186 (5), 695-704, 1997 | 276 | 1997 |
| Ten-year results of the PORTEC-2 trial for high-intermediate risk endometrial carcinoma: improving patient selection for adjuvant therapy BG Wortman, CL Creutzberg, H Putter, IM Jürgenliemk-Schulz, JJ Jobsen, ... British journal of cancer 119 (9), 1067-1074, 2018 | 266 | 2018 |
toos daemenBestätigte E-Mail-Adresse bei umcg.nl
